Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1955 1
1968 1
1978 1
1985 1
1987 2
1988 1
1989 5
1990 6
1991 10
1992 15
1993 10
1994 16
1995 13
1996 8
1997 11
1998 9
1999 13
2000 19
2001 11
2002 18
2003 11
2004 17
2005 18
2006 26
2007 29
2008 33
2009 29
2010 34
2011 33
2012 30
2013 39
2014 36
2015 39
2016 23
2017 15
2018 15
2019 11
2020 5
2021 6
2022 7
2023 4
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

559 results

Results by year

Filters applied: . Clear all
Page 1
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Jung KS, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J. Karlas T, et al. Among authors: marcellin p. J Hepatol. 2017 May;66(5):1022-1030. doi: 10.1016/j.jhep.2016.12.022. Epub 2016 Dec 28. J Hepatol. 2017. PMID: 28039099
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang WL, Bae H, Sharma M, Janssen HLA, Pan CQ, Çelen MK, Furusyo N, Shalimar D, Yoon KT, Trinh H, Flaherty JF, Gaggar A, Lau AH, Cathcart AL, Lin L, Bhardwaj N, Suri V, Mani Subramanian G, Gane EJ, Buti M, Chan HLY; GS-US-320-0110; GS-US-320-0108 Investigators. Agarwal K, et al. Among authors: marcellin p. J Hepatol. 2018 Apr;68(4):672-681. doi: 10.1016/j.jhep.2017.11.039. Epub 2018 Jan 17. J Hepatol. 2018. PMID: 29756595 Clinical Trial.
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.
Chan HLY, Buti M, Lim YS, Agarwal K, Marcellin P, Brunetto M, Chuang WL, Janssen HLA, Fung S, Izumi N, Abdurakhmanov D, Jabłkowski M, Celen MK, Ma X, Caruntu F, Flaherty JF, Abramov F, Wang H, Camus G, Osinusi A, Pan CQ, Shalimar, Seto WK, Gane E; GS-US-320-0110 and GS-US-320-0108 investigators. Chan HLY, et al. Among authors: marcellin p. Am J Gastroenterol. 2024 Mar 1;119(3):486-496. doi: 10.14309/ajg.0000000000002468. Epub 2023 Aug 9. Am J Gastroenterol. 2024. PMID: 37561058 Free PMC article. Clinical Trial.
Recent advances in hepatology.
Marcellin P, Estrabaud E. Marcellin P, et al. Liver Int. 2017 Jan;37 Suppl 1:3-6. doi: 10.1111/liv.13323. Liver Int. 2017. PMID: 28052630 No abstract available.
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, Hui AJ, Lim YS, Mehta R, Janssen HL, Acharya SK, Flaherty JF, Massetto B, Cathcart AL, Kim K, Gaggar A, Subramanian GM, McHutchison JG, Pan CQ, Brunetto M, Izumi N, Marcellin P; GS-US-320-0108 Investigators. Buti M, et al. Among authors: marcellin p. Lancet Gastroenterol Hepatol. 2016 Nov;1(3):196-206. doi: 10.1016/S2468-1253(16)30107-8. Epub 2016 Sep 22. Lancet Gastroenterol Hepatol. 2016. PMID: 28404092 Clinical Trial.
Staging Fibrosis in Chronic Viral Hepatitis.
Cardoso AC, Figueiredo-Mendes C, Villela-Nogueira CA, Marcellin P. Cardoso AC, et al. Among authors: marcellin p. Viruses. 2022 Mar 23;14(4):660. doi: 10.3390/v14040660. Viruses. 2022. PMID: 35458391 Free PMC article. Review.
Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection.
van Buuren N, Ramirez R, Turner S, Chen D, Suri V, Aggarwal A, Moon C, Kim S, Kornyeyev D, Bui N, Bhardwaj N, Chan HL, Marcellin P, Buti M, Wallin J, Gaggar A, Fletcher SP, Diehl L, Li L, Mo H, Feierbach B. van Buuren N, et al. Among authors: marcellin p. JHEP Rep. 2021 Oct 24;4(1):100388. doi: 10.1016/j.jhepr.2021.100388. eCollection 2022 Jan. JHEP Rep. 2021. PMID: 34950863 Free PMC article.
Improving performance of liver biopsy in fibrosis assessment.
Asselah T, Marcellin P, Bedossa P. Asselah T, et al. Among authors: marcellin p. J Hepatol. 2014 Aug;61(2):193-5. doi: 10.1016/j.jhep.2014.03.006. Epub 2014 Mar 17. J Hepatol. 2014. PMID: 24650692 Free article. No abstract available.
New therapies for hepatitis delta virus infection.
Loureiro D, Castelnau C, Tout I, Boyer N, Narguet S, Menasria Benazzouz S, Louis Z, Pons-Kerjean N, Giuly N, Marcellin P, Mansouri A, Asselah T. Loureiro D, et al. Among authors: marcellin p. Liver Int. 2021 Jun;41 Suppl 1:30-37. doi: 10.1111/liv.14838. Liver Int. 2021. PMID: 34155804 Review.
Future treatments for hepatitis delta virus infection.
Asselah T, Loureiro D, Tout I, Castelnau C, Boyer N, Marcellin P, Mansouri A. Asselah T, et al. Among authors: marcellin p. Liver Int. 2020 Feb;40 Suppl 1:54-60. doi: 10.1111/liv.14356. Liver Int. 2020. PMID: 32077603 Review.
559 results